S.F. Bellon
Foghorn Therapeutics (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Advanced biosensing and bioanalysis techniques, Histone Deacetylase Inhibitors Research, Ubiquitin and proteasome pathways
Most-Cited Works
- → An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells(2016)345 cited
- → Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture−Activity Relationships(2008)222 cited
- → Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials(2016)214 cited
- → A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications(2015)211 cited
- → The structure of phosphorylated P38γ is monomeric and reveals a conserved activation-loop conformation(1999)133 cited
- → Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains(2016)118 cited
- → Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)(2016)111 cited
- → Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase(2010)105 cited
- → Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors(2013)103 cited
- → Evolution of a Highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor(2007)91 cited